Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

  • participants needed
  • sponsor
    Massachusetts General Hospital
Updated on 1 December 2022
chronic myeloid leukemia
graft versus host disease
myeloid leukemia
lymphoid leukemia
chronic lymphocytic leukemia
bone marrow transplant
multiple myeloma
hodgkin's disease
myeloproliferative disorder
immunosuppressive agents
kidney transplant
treatment regimen
blood disorder
bone marrow procedure
hematologic disorder
lymphocytic leukemia
chemotherapy regimen
cancer treatment
allogeneic bone marrow transplantation
diamond-blackfan anemia
sickle cell anemia
kidney disease


The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease. We expect to have about 10 people participate in this study.

Additionally, because the same person who is donating the kidney will also be donating the bone marrow, there may be a smaller chance of kidney rejection and less need for long-term use of anti-rejection drugs.

Traditionally, very strong cancer treatment drugs (chemotherapy) and radiation are used to prepare a subject's body for bone marrow transplant. This is associated with a high risk for serious complications, even in subjects without kidney disease. This therapy can be toxic to the liver, lungs, mucous membranes, and intestines. Additionally, it is believed that standard therapy may be associated with a higher risk of a complication called graft versus host disease (GVHD) where the new donor cells attack the recipient's normal body. Recently, less intense chemotherapy and radiation regimens have been employed (these are called reduced intensity regimens) which cause less injury and GVHD to patients, and thus, have allowed older and less healthy patients to undergo bone marrow transplant. In this study, a reduced intensity regimen of chemotherapy and radiation will be used with the intent of producing fewer toxicities than standard therapy.

Typical therapy following a standard kidney transplant includes multiple lifelong medications that aim to prevent the recipient's body from attacking or rejecting the donated kidney. These are called immunosuppressant drugs and they work by "quieting" the recipient's immune system to allow the donated kidney to function properly. One goal in our study is to decrease the duration you will need to be on immunosuppressant drugs following your kidney transplant as the bone marrow transplant will provide you with the donor's immune system which should not attack the donor kidney.

Condition chronic renal insufficiency, Bone marrow disorder, Bone marrow disorder, Diamond-Blackfan anemia, childhood ALL, Lymphocytic Leukemia, Acute, Hodgkin's Disease, Hodgkin's Disease, Multiple Myeloma, Multiple Myeloma, Thalassemia, Thalassemia, Chronic renal failure, Lymphoma, Non-Hodgkin's Lymphoma, Preleukemia, Autoimmune disease, Autoimmune disease, Anemia, Anemia, Anemia; Non-Hodgkin’s Lymphoma, Aplastic Anemia, Aplastic Anemia, Anemia; Non-Small-Cell Lung Cancer, Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), Acute myeloid leukemia, Amyloidosis, Amyloidosis, Myelosclerosis with myeloid metaplasia, Myelofibrosis, Autoimmunity, Lymphoproliferative Disorder, Lymphoproliferative disorders, Lymphoma, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, MYELOPROLIFERATIVE DISORDER, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS), SICKLE CELL ANEMIA, Sickle Cell Disease, Chronic myeloid leukemia, Chronic myeloid leukemia, Lymphocytic Leukemia, Chronic, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), AL Amyloidosis, Primary Amyloidosis, Myeloproliferative Neoplasms, Anemia; Non-Small-Cell Lung Cancer, Lymphocytic Leukemia, Acute, Anemia; Non-Hodgkin’s Lymphoma, Myelofibrosis, Sickle Cell Disease, Lymphoproliferative disorders, acute lymphoblastic leukemia, chronic kidney disease, leukemia, acute lymphoblastic, myelodysplastic syndromes, myeloproliferative neoplasm, myeloproliferative disorders, non-hodgkin's lymphoma (nhl), leukemia chronic lymphocytic, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma, chronic kidney disease (ckd), autoimmune diseases, autoimmune disorder, autoimmune disorders, multiple myeloma (mm), myelodysplastic syndrome (mds), hodgkin, hodgkin's lymphomas, hodgkin lymphomas, hodgkins lymphoma, hodgkin's lymphoma, acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), acute myelogenous leukemia, anll, acute myeloblastic leukemia, chronic myelogenous leukemia
Treatment Haploidentical Bone Marrow/Kidney
Clinical Study IdentifierNCT01758042
SponsorMassachusetts General Hospital
Last Modified on1 December 2022

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note